Johnson & Johnson $JNJ Shares Sold by Sapient Capital LLC

Key Points

• Sapient Capital LLC reduced its stake in Johnson & Johnson by 6.9%, selling 4,090 shares, and now holds 55,190 shares worth approximately $8.43 million.
• A variety of institutional investors have made recent trades, with GSG Advisors LLC notably increasing its stake in Johnson & Johnson by 71.4% during the same quarter.
• Johnson & Johnson recently reported $2.77 earnings per share for its last quarter, exceeding expectations, and announced a quarterly dividend of $1.30, yielding 2.9%.

Sapient Capital LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 6.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 55,190 shares of the company's stock after selling 4,090 shares during the period. Sapient Capital LLC's holdings in Johnson & Johnson were worth $8,430,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the first quarter worth approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $49,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $50,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. UBS Group lifted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $177.87.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $1.81 during trading on Friday, hitting $175.97. 25,617,065 shares of the stock were exchanged, compared to its average volume of 6,995,150. The company has a fifty day moving average price of $172.80 and a two-hundred day moving average price of $161.67. The company has a market cap of $423.80 billion, a PE ratio of 18.82, a P/E/G ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 EPS. The company's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.